EMD-10041
SIVrcm intasome
EMD-10041
Single-particle3.36 Å

Map released: 05/02/2020
Last modified: 10/07/2024
Sample Organism:
Simian immunodeficiency virus
Sample: SIVrcm intasome in complex with bictegravir
Fitted models: 6rwl (Avg. Q-score: 0.471)
Deposition Authors: Cherepanov P
,
Nans A
,
Cook N
Sample: SIVrcm intasome in complex with bictegravir
Fitted models: 6rwl (Avg. Q-score: 0.471)
Deposition Authors: Cherepanov P


Structural basis of second-generation HIV integrase inhibitor action and viral resistance.
Cook NJ
,
Li W
,
Berta D
,
Badaoui M
,
Ballandras-Colas A
,
Nans A
,
Kotecha A
,
Rosta E
,
Engelman AN
,
Cherepanov P
(2020) Science , 367 , 806 - 810










(2020) Science , 367 , 806 - 810
Abstract:
Although second-generation HIV integrase strand-transfer inhibitors (INSTIs) are prescribed throughout the world, the mechanistic basis for the superiority of these drugs is poorly understood. We used single-particle cryo-electron microscopy to visualize the mode of action of the advanced INSTIs dolutegravir and bictegravir at near-atomic resolution. Glutamine-148→histidine (Q148H) and glycine-140→serine (G140S) amino acid substitutions in integrase that result in clinical INSTI failure perturb optimal magnesium ion coordination in the enzyme active site. The expanded chemical scaffolds of second-generation compounds mediate interactions with the protein backbone that are critical for antagonizing viruses containing the Q148H and G140S mutations. Our results reveal that binding to magnesium ions underpins a fundamental weakness of the INSTI pharmacophore that is exploited by the virus to engender resistance and provide a structural framework for the development of this class of anti-HIV/AIDS therapeutics.
Although second-generation HIV integrase strand-transfer inhibitors (INSTIs) are prescribed throughout the world, the mechanistic basis for the superiority of these drugs is poorly understood. We used single-particle cryo-electron microscopy to visualize the mode of action of the advanced INSTIs dolutegravir and bictegravir at near-atomic resolution. Glutamine-148→histidine (Q148H) and glycine-140→serine (G140S) amino acid substitutions in integrase that result in clinical INSTI failure perturb optimal magnesium ion coordination in the enzyme active site. The expanded chemical scaffolds of second-generation compounds mediate interactions with the protein backbone that are critical for antagonizing viruses containing the Q148H and G140S mutations. Our results reveal that binding to magnesium ions underpins a fundamental weakness of the INSTI pharmacophore that is exploited by the virus to engender resistance and provide a structural framework for the development of this class of anti-HIV/AIDS therapeutics.